<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02128828</url>
  </required_header>
  <id_info>
    <org_study_id>H020</org_study_id>
    <nct_id>NCT02128828</nct_id>
  </id_info>
  <brief_title>Effect of Cenicriviroc on HIV Neurocognitive Impairment</brief_title>
  <official_title>H020: Single-Arm Open Label, Pilot Study of CCR5/CCR2 Inhibitor Cenicriviroc (CVC) for HIV Associated Neurocognitive Disorder (HAND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tobira Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hawaii</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that cenicriviroc will improve cognition in HIV infected individuals&#xD;
      with cognitive impairment. The investigators will study the effect of cenicriviroc on&#xD;
      cognition in 24 subjects over a 24 week period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-associated neurocognitive disease (HAND), particularly in its milder form, is estimated&#xD;
      to occur in greater than 30% of HIV infected individuals in the era of potent antiretroviral&#xD;
      therapy. As even mild disease leads to functional consequences with decreased ability to live&#xD;
      independently, HAND is of substantial public health concern. HIV-induced immune&#xD;
      activation/inflammation of monocytes (MO) may be primarily responsible for the development of&#xD;
      HAND.&#xD;
&#xD;
      Cenicriviroc is a combined CCR5 and CCR2 chemokine co-receptor antagonist. The investigators&#xD;
      hypothesize that dual CCR5 and CCR2 blockade with the use of CVC will lead to measurable&#xD;
      reductions in MO activation and lead to cognitive improvement by decreasing HIV infection of&#xD;
      MO and by interrupting the trafficking of such MO into the central nervous system.&#xD;
&#xD;
      The investigators propose a single arm, 24-week trial of CVC in 24 subjects with HIV-1&#xD;
      infection suppressed on ART (plasma HIV RNA &lt; 50 copies/ml) for 1 year or more with mild to&#xD;
      moderate cognitive impairment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 24 in Global Neuropsychological Performance</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Raw scores from individual performance on 14 validated neuropsychological tests meant to assess various cognitive domains were converted into standardized z-scores adjusted for age, sex, and education. Z-scores from all tests were aggregated and averaged to determine each subject's Global Neuropsychological Performance Score; NPZ-Global). Z-scores follow a normal distribution with scores &lt; '0' identifying poorer cognition than 'average' and scores &gt; &quot;0&quot; identifying better cognition than average with -1 and +1 represented 1 SD below or higher than average.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>AIDS Dementia Complex</condition>
  <condition>HIV-1-Associated Cognitive Motor Complex</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>cenicriviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cenicriviroc</intervention_name>
    <description>cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc</description>
    <arm_group_label>cenicriviroc</arm_group_label>
    <other_name>TBR-652</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  4.2.1.1 Documentation of HIV-1 infection by an FDA approved test at any time prior to&#xD;
             study entry&#xD;
&#xD;
          -  On ARV medication uninterrupted for &gt; 1 year leading up to the screening period&#xD;
&#xD;
          -  Screening plasma HIV RNA &lt; 50 copies/ml within 3 months of entry&#xD;
&#xD;
          -  Willingness for males and females of childbearing potential to utilize 2 effective&#xD;
             contraception methods (2 separate forms, one of which must be an effective barrier&#xD;
             method), be non-heterosexually active or have a an exclusive vasectomized partner from&#xD;
             screening throughout the duration of the study treatment and for 30 days following the&#xD;
             last dose of study drugs.&#xD;
&#xD;
          -  Age 18 to 70 years&#xD;
&#xD;
          -  Ability and willingness to provide written informed consent&#xD;
&#xD;
          -  Mild to moderate cognitive impairment with global neuropsychological (NP) test&#xD;
             (NPZglobal) score of &lt; -0.5 or a neurocognitive abnormality (&lt;-0.5) in at least one&#xD;
             cognitive domain known to be typically affected by HIV OR unimpaired&#xD;
&#xD;
          -  On antiretroviral (ARV) therapy consisting of nucleoside reverse transcriptase&#xD;
             inhibitors, atazanavir with/or without ritonavir, darunavir plus ritonavir,&#xD;
             dolutegravir, raltegravir or efavirenz.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving or used a CCR5 antagonist within 6 months of study entry&#xD;
&#xD;
          -  Plasma HIV RNA &gt; 100 copies/ml within 6 mo. of screening&#xD;
&#xD;
          -  HIV-2&#xD;
&#xD;
          -  Chronic hepatitis B (positive hepatitis B surface antigen)&#xD;
&#xD;
          -  Chronic hepatitis C (positive hepatitis C antibody), except with proof of viral&#xD;
             clearance and normal liver function tests&#xD;
&#xD;
          -  Active or chronic liver disease&#xD;
&#xD;
          -  Active or inadequately treated tuberculosis infection, or inadequate treatment for a&#xD;
             positive purified protein derivative test. Adequate treatment meets current&#xD;
             recommendations of the Center for Disease Control, NIH and the HIV Medicine&#xD;
             Association of the Infectious Diseases Society of America (IDSA) guidelines or other&#xD;
             Center for Disease Control recommendations if patient was treated before the current&#xD;
             recommendations or before coinfection with HIV.&#xD;
&#xD;
          -  Prior/current diagnosis with other intracellular pathogens (Listeria monocytogenes,&#xD;
             Toxoplasma gondii, and Cryptococcus neoformans).&#xD;
&#xD;
          -  Uncontrolled seizures&#xD;
&#xD;
          -  Current or past malignancies excluding basal cell cancer and Kaposi's sarcoma (skin).&#xD;
&#xD;
          -  Immunomodulator, HIV vaccine, any other vaccine, or investigational therapy within 30&#xD;
             days of entry.&#xD;
&#xD;
          -  Requirement for acute therapy for AIDS-defining or other serious medical illnesses&#xD;
             within 14 days of entry.&#xD;
&#xD;
          -  Other chronic illnesses including hematologic, pulmonary, autoimmune diseases and&#xD;
             endocrinopathies, except for stable controlled diabetes or cardiovascular disease in&#xD;
             the view of the investigator and stable testosterone or thyroid therapy.&#xD;
&#xD;
          -  Known hypersensitivity to CVC or its excipients&#xD;
&#xD;
          -  Anticipated need for prescription medication not allowed in the study. Unwilling to&#xD;
             stop eating grapefruit or using St. John's wort).&#xD;
&#xD;
          -  Chronic use of over the counter medications unless approved by Study Investigator&#xD;
&#xD;
          -  Hemoglobin &lt; 8.5; Absolute neutrophil count &lt; 1000; Platelet count &lt; 100,000; serum&#xD;
             glutamate oxaloacetate and pyruvate transaminase &gt; 2.5x upper limit of normal ; Lipase&#xD;
             &gt; 2.0 x upper limit of normal&#xD;
&#xD;
          -  Estimated creatinine clearance &lt; 30 mL/min(Cockcroft and Gault 1979)&#xD;
&#xD;
          -  Bradycardia, sinus rhythm &lt;50 beats/min (bpm).&#xD;
&#xD;
          -  Presence of any condition that would interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of the drug&#xD;
&#xD;
          -  Current active illicit substance or alcohol use or abuse which, in the judgment of the&#xD;
             Investigator, will interfere with the patient's ability to comply with protocol&#xD;
             requirements&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  History of moderate (Child-Pugh class B) or severe (Child-Pugh C) hepatic impairment&#xD;
&#xD;
          -  Patients, who, in the opinion of the Investigator, are unable to comply with the&#xD;
             dosing schedule and protocol evaluation or for whom the study may not be advisable&#xD;
&#xD;
          -  For MRI substudy [impaired]: Any factor that precludes MRI scan including presence of&#xD;
             metal or exposure to metal work (e.g. metal grinder/worker) and claustrophobia&#xD;
&#xD;
          -  For MRI substudy [impaired]: Any central nervous system pathology which, in the&#xD;
             judgment of the investigator, will interfere with the ability to assess study change&#xD;
             in magnetic resonance spectroscopy&#xD;
&#xD;
          -  4.2.2.28 For lumbar puncture substudy: Thrombocytopenia or other bleeding disorders&#xD;
             (including ongoing anticoagulant therapy), suspected increased intracranial pressure&#xD;
             or spinal epidural abscess, or any other factor which would increase risk of&#xD;
             complications following lumbar puncture&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cecilia Shikuma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hawaii - Hawaii Center for AIDS (HICFA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clint Spencer Clinic</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <results_first_submitted>August 12, 2017</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2020</results_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Hawaii</investigator_affiliation>
    <investigator_full_name>Cecilia Shikuma</investigator_full_name>
    <investigator_title>Professor, Dept of Medicine</investigator_title>
  </responsible_party>
  <keyword>AIDS Dementia Complex</keyword>
  <keyword>HIV-1-Associated Cognitive Motor Complex</keyword>
  <keyword>Human Immunodeficiency Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>AIDS Dementia Complex</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cenicriviroc</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cenicriviroc</title>
          <description>cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily&#xD;
cenicriviroc: cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cenicriviroc</title>
          <description>cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily&#xD;
cenicriviroc: cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="46" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 24 in Global Neuropsychological Performance</title>
        <description>Raw scores from individual performance on 14 validated neuropsychological tests meant to assess various cognitive domains were converted into standardized z-scores adjusted for age, sex, and education. Z-scores from all tests were aggregated and averaged to determine each subject's Global Neuropsychological Performance Score; NPZ-Global). Z-scores follow a normal distribution with scores &lt; '0' identifying poorer cognition than 'average' and scores &gt; &quot;0&quot; identifying better cognition than average with -1 and +1 represented 1 SD below or higher than average.</description>
        <time_frame>baseline, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cenicriviroc</title>
            <description>cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily&#xD;
cenicriviroc: cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Global Neuropsychological Performance</title>
          <description>Raw scores from individual performance on 14 validated neuropsychological tests meant to assess various cognitive domains were converted into standardized z-scores adjusted for age, sex, and education. Z-scores from all tests were aggregated and averaged to determine each subject's Global Neuropsychological Performance Score; NPZ-Global). Z-scores follow a normal distribution with scores &lt; '0' identifying poorer cognition than 'average' and scores &gt; &quot;0&quot; identifying better cognition than average with -1 and +1 represented 1 SD below or higher than average.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".24" lower_limit="-.03" upper_limit=".46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cenicriviroc</title>
          <description>cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily&#xD;
cenicriviroc: cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cecilia Shikuma</name_or_title>
      <organization>University of Hawaii</organization>
      <phone>808 692-1328</phone>
      <email>shikuma@hawaii.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

